Logo image of NN6.DE

NANOREPRO AG (NN6.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:NN6 - DE0006577109 - Common Stock

1.515 EUR
-0.06 (-3.81%)
Last: 1/15/2026, 7:00:00 PM

NN6.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap19.54M
Revenue(TTM)5.13M
Net Income(TTM)-1.72M
Shares12.90M
Float12.36M
52 Week High2.12
52 Week Low1.17
Yearly Dividend0.15
Dividend Yield6.98%
EPS(TTM)-0.14
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2012-10-09
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
NN6.DE short term performance overview.The bars show the price performance of NN6.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 -6

NN6.DE long term performance overview.The bars show the price performance of NN6.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30

The current stock price of NN6.DE is 1.515 EUR. In the past year, price increased by 5.57%.

NANOREPRO AG / NN6 Daily stock chart

NN6.DE Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NN6.DE. When comparing the yearly performance of all stocks, NN6.DE is a bad performer in the overall market: 72.3% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NN6.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to NN6.DE. NN6.DE has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NN6.DE Financial Highlights

Over the last trailing twelve months NN6.DE reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 39.13% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -4.53%
ROE -4.65%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%22.22%
Sales Q2Q%37.29%
EPS 1Y (TTM)39.13%
Revenue 1Y (TTM)44.1%

NN6.DE Forecast & Estimates

5 analysts have analysed NN6.DE and the average price target is 4.59 EUR. This implies a price increase of 202.97% is expected in the next year compared to the current price of 1.515.

For the next year, analysts expect an EPS growth of -1% and a revenue growth 232.82% for NN6.DE


Analysts
Analysts84
Price Target4.59 (202.97%)
EPS Next Y-1%
Revenue Next Year232.82%

NN6.DE Ownership

Ownership
Inst Owners9.02%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

NN6.DE Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
2M6.DE MEDTRONIC PLC 17.6 109.00B
1MDT.MI MEDTRONIC PLC 17.04 105.52B
SHL.DE SIEMENS HEALTHINEERS AG 19.58 52.79B
1SHL.MI SIEMENS HEALTHINEERS AG 19.62 52.88B
PHI1.DE KONINKLIJKE PHILIPS NV 17.66 25.16B
PHIA.AS KONINKLIJKE PHILIPS NV 17.62 25.11B
BIM.PA BIOMERIEUX 27.51 12.57B
OBCK.DE OTTOBOCK SE & CO KGAA 141.38 4.25B
DIA.MI DIASORIN SPA 22.95 4.25B
AFX.DE CARL ZEISS MEDITEC AG - BR 24.63 3.55B
DRW3.DE DRAEGERWERK AG - PREF 12.33 1.49B
ELN.MI EL.EN. SPA 22.75 1.17B

Related stock screener links

About NN6.DE

Company Profile

NN6 logo image NanoRepro AG engages in the development, manufacture, and distribution of diagnostic tests and food supplements for home and professional use. The company is headquartered in Marburg An Der Lahn, Hessen and currently employs 20 full-time employees. The company went IPO on 2012-10-09. The firm is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.

Company Info

NANOREPRO AG

Untergasse 8

Marburg an der Lahn HESSEN DE

Employees: 20

NN6 Company Website

NN6 Investor Relations

Phone: 496421951449

NANOREPRO AG / NN6.DE FAQ

What does NANOREPRO AG do?

NanoRepro AG engages in the development, manufacture, and distribution of diagnostic tests and food supplements for home and professional use. The company is headquartered in Marburg An Der Lahn, Hessen and currently employs 20 full-time employees. The company went IPO on 2012-10-09. The firm is engaged in the research of stem cells, which are used in the medical treatment due to their ability to self-renew and differentiate to a range of specialized cell types. Nanorepro AG gathers samples of patients’ stem cells and stores them for the future use. Its portfolio also comprises OTC rapid diagnostic tests, such as OvuQUICK, an ovulation test for women; GraviQUICK, a pregnancy test; MenoQUICK, a menopause test; VagiQUICK, a vaginal yeast test; GlutenCHECK, a test to detect celiac disease; CholesterinCHECK, a test to measure the level of total cholesterol, HDL and LDL, as well as FertiQUICK, a fertility test for men.


What is the stock price of NANOREPRO AG today?

The current stock price of NN6.DE is 1.515 EUR. The price decreased by -3.81% in the last trading session.


Does NN6 stock pay dividends?

NANOREPRO AG (NN6.DE) has a dividend yield of 6.98%. The yearly dividend amount is currently 0.15.


What is the ChartMill technical and fundamental rating of NN6 stock?

NN6.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the GICS sector and industry of NN6 stock?

NANOREPRO AG (NN6.DE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Who owns NANOREPRO AG?

You can find the ownership structure of NANOREPRO AG (NN6.DE) on the Ownership tab.